Citicoline (CDP-choline) is sold as an over-the-counter brain-health supplement in the United States and several other markets, so brands abroad sometimes assume a Japan-made citicoline product is simply a matter of finding the right factory. It isn’t. In Japan, citicoline exists only as an approved prescription medicine, and a Japanese factory will not treat it as a food ingredient until its classification is confirmed by the authorities.
This guide explains that status, and which brain-focus ingredients a Japanese factory can actually work with instead.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a brain-focus product made in Japan? We check the full formula against Japanese food law first, before you commit to an ingredient. See Japan-made supplement OEM.
Citicoline’s status in Japan
Citicoline is included in the Japanese Pharmacopoeia and sold in Japan only as a prescription medicine, with no established history of sale as a food, so its use in a food supplement would first need its classification confirmed by the Japanese authorities.
Japan’s pharmaceutical name database lists citicoline as a substance included in the Japanese Pharmacopoeia (日局収載), Japan’s official pharmaceutical standards reference. In Japanese clinical practice, citicoline sodium is formulated as an injectable medicine used for conditions such as head trauma, stroke and reduced consciousness. This guide did not find citicoline named on the Ministry of Health, Labour and Welfare’s published illustrative list of substances treated exclusively as medicines, but its only established use in Japan is as a pharmacopoeia-listed prescription drug, with no comparable history as a food ingredient there. Under Japan’s “Standards on the Scope of Pharmaceuticals,” a substance with an established, exclusively pharmaceutical use in Japan is treated as falling under the medicine side of the food-drug boundary in practice, separate from whether it appears by name on the illustrative list.
In practice, this means:
- A Japanese GMP factory cannot currently manufacture a citicoline tablet, capsule, powder or drink as a food, because citicoline’s only established use in Japan is as a prescription pharmaceutical ingredient.
- This is different from citicoline’s status in some other markets. A free-base or “inner salt” form of citicoline has been affirmed as a food ingredient in some markets outside Japan; that status does not transfer to Japan, where the ingredient’s only established use is as a medicine.
How this compares elsewhere
Citicoline’s status varies by market, which is exactly why it needs checking market by market rather than assumed from one country’s rules.
| Market | Status |
|---|---|
| Japan | Sold only as a prescription medicine (Japanese Pharmacopoeia-listed); no established food-ingredient use |
| United States | A free-base form of citicoline has been used as a dietary supplement ingredient, sold over the counter |
| European Union | A free-base form of citicoline was authorised as a Novel Food ingredient by the European Commission following a 2013 EFSA safety opinion |
Confirm the current rule in each market you plan to sell in directly with that market’s regulator before you commit to a citicoline product; this table describes general positions, not a guarantee for any specific formulation or dose.
💬 Building a brain-focus range and unsure which ingredients a Japanese factory can actually use? Tell us your concept and we check it against Japanese food law before you commit.
What to use instead
Japan can manufacture several other ingredients that are studied in relation to memory and cognitive performance and are permitted as foods, without the regulatory block that citicoline carries.
Three ingredients used in Japanese brain-focus products are permitted as foods and have their own study evidence, each covered in its own guide with honest treatment of what the evidence does and does not show:
- Ginkgo biloba — a long-studied botanical extract used in cognitive-focused products.
- PQQ — a compound studied in relation to cognitive performance.
- Phosphatidylserine — a phospholipid notified in Japan for word-recall memory support, though the wider trial evidence is mixed.
None of these ingredients works the same way as citicoline, and none should be marketed as a citicoline substitute or equivalent — that would overstate the evidence and misrepresent how each ingredient is actually studied. Each has its own dose, evidence base and formulation considerations, covered in its own guide.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product — citicoline cannot pass this check without a confirmed classification, given its medicine-only history in Japan.
This is the same check that applies to every ingredient on this site. See the Japan-made supplement OEM page for how we check a full formula before quoting.
Before you ask about a brain-focus product
Tell us the cognitive-related benefit you want to build around, and we confirm which ingredients a Japanese factory can actually use before any formulation work begins.
- The cognitive or focus-related outcome you want the product associated with
- Any ingredients you already have in mind, so we can check their Japanese status first
- Dosage form preference
- Countries you will sell in, and each market’s rules on brain-focus ingredients and claims
- First order and annual volume
💬 Have a brain-focus concept in mind? Send it to us and we will tell you plainly which ingredients Japan can make, before any formulation work begins.
Frequently asked questions
1. Can a Japanese factory make a citicoline supplement at a low dose?
No. Citicoline’s status in Japan is tied to its established use as a pharmaceutical ingredient, not to a specific dose. A Japanese factory cannot currently manufacture it as a food regardless of the amount used.
2. Why is citicoline sold as a supplement in the United States but not made as a food in Japan?
Countries assess ingredients based on their own regulatory history. In the United States, a free-base form of citicoline has an established use as a dietary supplement ingredient. In Japan, citicoline’s only established use has been as a prescription medicine, so it falls on the medicine side of Japan’s food-drug boundary.
3. Is this likely to change?
This guide found no indication of a pending move to establish a food-ingredient status for citicoline in Japan. Brands should plan around the current situation rather than an anticipated change.
4. Can I import a citicoline product made elsewhere and sell it through a Japanese company?
That is a different question from manufacturing, and depends on import and market-entry rules rather than this guide’s scope of Japanese food manufacturing. What this guide confirms is that a Japanese factory cannot manufacture the product as a food.
5. Are ginkgo biloba, PQQ and phosphatidylserine equivalent to citicoline?
No. Each works differently and has its own separate evidence base. They are alternatives that Japan can legally manufacture as foods, not substitutes with matching effects.
Sources: Japan Standard Drug Names (JAN) database entry for citicoline (シチコリン), listing it as included in the Japanese Pharmacopoeia (jpdb.nihs.go.jp); Japanese pharmaceutical package-insert and drug-database listings describing citicoline sodium injectable medicines for stroke, head trauma and consciousness disorders (e.g. clinicalsup.jp drug listing, kegg.jp medicinal-product entries); EFSA, “Scientific Opinion on the safety of ‘citicoline’ as a Novel Food ingredient”, EFSA Journal 2013. Checked on 25 September 2026.